Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03543969
Title Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors H. Lee Moffitt Cancer Center and Research Institute
Indications

melanoma

Therapies

Cobimetinib + Vemurafenib

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST